Dudkiewicz G, Wójcik J, Gawrońska-Szklarz B
Kliniki Chorób Wewnetrznych PAM, Szczecinie.
Neurol Neurochir Pol. 1994 Nov-Dec;28(6):845-52.
The problem of the effects of metabolic changes on drug pharmacokinetics is not yet sufficiently known. Phenytoin was used for the assessment of the effects of lipid profile disturbances on drug pharmacokinetics. Phenytoin is a lipophilic substance. It was shown that hyperlipidaemia changed phenytoin pharmacokinetics and the pattern of these changes depended on the type of hyperlipidaemia. In hypercholesterolaemia and in mixed hyperlipidaemia the level of free phenytoin was raised in the blood. It should be remembered that hypercholesterolaemia and mixed hyperlipidaemia are conditions increasing the risk of phenytoin overdosage and this should be considered in establishing drug dosage.
代谢变化对药物药代动力学的影响问题尚未得到充分了解。苯妥英被用于评估血脂异常对药物药代动力学的影响。苯妥英是一种亲脂性物质。结果表明,高脂血症改变了苯妥英的药代动力学,且这些变化的模式取决于高脂血症的类型。在高胆固醇血症和混合性高脂血症中,血液中游离苯妥英的水平升高。应记住,高胆固醇血症和混合性高脂血症会增加苯妥英过量的风险,在确定药物剂量时应考虑到这一点。